术前外周血循环肿瘤DNA在肝细胞癌微循环血管侵犯预测中的应用价值分析

doi:10.3969/j.issn.1009-976X.2023.02.002

岭南现代临床外科 ›› 2023, Vol. 23 ›› Issue (02): 100-105.DOI: 10.3969/j.issn.1009-976X.2023.02.002

术前外周血循环肿瘤DNA在肝细胞癌微循环血管侵犯预测中的应用价值分析

程诺^1,2, 任庆旗^1,2, 袁建玲^1,2, 吴柳盛^1,2, 林泽伟^1,2,*

1.安徽医科大学北京大学深圳医院临床学院,广东深圳 518036;
2.北京大学深圳医院肝胆胰外科,广东深圳 518036

通讯作者: *林泽伟,Email：szlinzw@126.com
基金资助:
深圳市科技创新委员会（JCYJ20190809095801653; JCYJ20190809100217290）

The analysis of application value of preoperative peripheral blood circulating tumor DNA in the prediction of microvascular invasion of hepatocellular carcinoma

CHENG Nuo^1,2, REN Qing-qi^1,2, YUAN Jian-ling^1,2, WU Liu-sheng^1,2, LIN Ze-wei^1,2

1. Peking University Shenzhen Hospital, Clinical College of Anhui Medical University, Shenzhen 518036, Guangdong, China;
2. Department of Hepatobiliary and Pancreatic Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China

Received:2022-12-12 Online:2023-04-20 Published:2023-05-22
Contact: LIN Ze-wie, szlinzw@126.com

摘要/Abstract

摘要： 目的探讨术前外周血中采集的ctDNA针对肝细胞肝癌（HCC）病人的微循环血管浸润（MVI）是否存在预测价值。方法收集59例来自北京大学深圳医院的确诊原发性肝癌的患者,术前一周内收集所有患者肿瘤相关术前的临床资料以及外周血ctDNA;术中采集患者的肿瘤标本进行病理分析判断有无MVI发生。采用logistic回归模型进行单因素和多因素分析确定影响MVI的独立危险因素。结果在59例纳入研究队列的患者中,MVI阳性的患者有37例,MVI阴性患者有22例。采用受试者工作特性曲线（ROC）分析显示：ctDNA预测肝癌MVI发生的最佳截断值为0.80,曲线下面积为0.813,影响肝癌发生的危险因素分析：单因素分析显示：ALT>40 U/L,较晚的TNM、BCLC分期,肿瘤最大径>3.5 cm和ctDNA >0.80与肝癌MVI的发生有关。多因素分析显示：ctDNA>0.80、肿瘤最大径>3.5 cm、较晚的TNM分期,是影响肝癌MVI发生的独立危险因素。根据筛选出的危险因素建立列线图可更加直观的反应肝癌患者MVI的风险因素。比较不同水平ctDNA评分下的肝癌患者的临床特征的不同：根据ctDNA评分的最佳截断值将59例患者分为32例低ctDNA评分组及27例高ctDNA患者组,其中AFP>400 ng/mL、TBIL>12 μmol/L、APTT>39.5 s、PIVKA-II>40 mAU/mL、肿瘤最大径>3.5 cm及微血管侵犯阳性的患者在两组中的差异具有统计学意义。结论术前外周血ctDNA可用于肝癌MVI的预测,并且对于肝癌患者的患者术前患者精准治疗提供参考。

关键词: 循环肿瘤DNA, 肝细胞肝癌, 微循环血管侵犯, 预测价值

Abstract: Objective This study was conducted to investigate the value of ctDNA derived from peripheral blood in predicting microvascular invasion （MVI） of HCC. Methods The retrospective case-control study was performed, and the patients with a diagnosis of HCC from Peking University Hospital were enrolled, whose clinical data related to tumor and the peripheral blood ctDNA were collected. The MVI was diagnosed by the pathological analysis of the tumor specimens collected intraoperatively. Results Fifty-nine patients were enrolled in this study, including 37 cases with MVI and 22 cases without MVI. The independent risk factors related to MVI were analyzed by univariate analysis and multivariate analysis with the Logistic retrospective model. Result of receiver operating characteristic curve （ROC）： the cut-off value of ctDNA score level in predicting microvascular invasion of HCC was 0.80, and the area under curve was 0.813. The analysis of influencing factors for microvascular invasion： univariate analysis： ALT>40 U/L, higher TNM, BCLC stage, larger tumor size （>3.5 cm） and ctDNA >0.80 were related to MVI in HCC. And multiple-factor analysis showed that ctDNA >0.80, larger tumor size（>3.5 cm） and late TNM stage were independent risk factors for the development of MVI. The nomogram constructed based on these screened risk factors directly predicted the risk of MVI in HCC patients. Comparison of clinical data of different levels of HCC patient： 59 HCC patients were divided into low ctDNA score group of 32 cases and high ctDNA group of 27 cases based on the cut-off value of ctDNA score. And the case of AFP>400 ng/mL, TBIL>12 μmol/L, APTT>39.5 s, PIVKA-II>40 mAU/mL, the largest size of tumor >3.5 cm and microvascular invasion respectively were significant differenct in the above indicators between these two groups. Conclusion The preoperative ctDNA derived from peripheral blood can be used to predict the preoperative microvascular invasion in HCC, and has a reference significance to the preoperative individualized treatment.

Key words: ctDNA, hepatocellular carcinoma, microvascular invasion, predicting value

中图分类号:

R735.7

程诺, 任庆旗, 袁建玲, 吴柳盛, 林泽伟. 术前外周血循环肿瘤DNA在肝细胞癌微循环血管侵犯预测中的应用价值分析[J]. 岭南现代临床外科, 2023, 23(02): 100-105.

CHENG Nuo, REN Qing-qi, YUAN Jian-ling, WU Liu-sheng, LIN Ze-wei. The analysis of application value of preoperative peripheral blood circulating tumor DNA in the prediction of microvascular invasion of hepatocellular carcinoma[J]. Lingnan Modern Clinics In Surgery, 2023, 23(02): 100-105.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Zhou M, Wang H, Zeng X, et al.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study2017[J]. The Lancet, 2019, 394(10204): 1145-1158.
[3] Ang SF, Ng ES, Li H, et al.The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma[J]. PLoS One, 2015, 10(4): e0118658.
[4] Erstad DJ, Tanabe KK.Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma[J]. Ann Surg Oncol, 2019, 26(5): 1474-1493.
[5] 周晓涵, 台蕴泽, 周娟. 术前预测肝细胞癌微血管侵犯的研究进展[J]. 中国肿瘤临床, 2022, 49(01): 47-52.
[6] 李晨光, 窦文广, 付义彬, 等. CT技术联合CTCs、AFP对肝细胞癌微血管侵犯的预测价值[J]. 肝脏, 2021, 26(10): 1112-1114+1122.
[7] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(02): 143-168.
[8] 雷正清. 早期肝癌微血管侵犯的术前预测和对肝切除术切缘选择的影响[D]. 第二军医大学, 2016.
[9] Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies [J]. Sci Transl Med, 2014, 6(224): 224ra24.
[10] Cai H, Zhang Y, Zhang H, et al.Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy[J]. J Surg Oncol, 2020, 121(6): 1007-1014.
[11] 金赟, 李江涛. 肝癌细胞侵犯微血管的临床相关因素及分子标志物的研究进展[J]. 临床肝胆病杂志, 2013, 29(07): 550-553.
[12] Eguchi S, Takatsuki M, Hidaka M, et al.Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from229 consecutive cases of curative liver resection[J]. World J Surg, 2010, 34(5): 1034-1038.
[13] 谭君心, 符纯川, 李国华. 血小板淋巴细胞比值和肿瘤直径与肝细胞癌微血管侵犯的相关性[J]. 标记免疫分析与临床, 2020, 27(01): 48-52.
[14] Li S, Zeng Q, Liang R, et al.Using Systemic Inflammatory Markers to Predict Microvascular Invasion Before Surgery in Patients With Hepatocellular Carcinoma[J]. Front Surg, 2022, 9: 833779.
[15] Higuera M, Vargas-Accarino E, Torrens M, et al.Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management[J], Cancers (Basel), 2022, 14(16): 3875.

术前外周血循环肿瘤DNA在肝细胞癌微循环血管侵犯预测中的应用价值分析

The analysis of application value of preoperative peripheral blood circulating tumor DNA in the prediction of microvascular invasion of hepatocellular carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

[1]	黄沾任, 宁金月, 李汉卿, 陈念平. 免疫联合靶向治疗在晚期肝癌转化治疗中的研究进展[J]. 岭南现代临床外科, 2022, 22(01): 110-114.
[2]	宋燕州, 康志龙, 苏一男, 张毅明, 赵新, 李志伟, 李伟. NEK7在原发性肝细胞肝癌患者中表达及其临床意义[J]. 岭南现代临床外科, 2021, 21(06): 608-613.
[3]	苏汝平, 李妮, 钟漓, 赵志. 腹腔镜肝切除联合脾动脉结扎术治疗肝癌合并门脉高压症的疗效分析[J]. 岭南现代临床外科, 2021, 21(04): 415-418.
[4]	赵兵兵，李梓涛，胡伟东，薛静，李明意*. 肝细胞肝癌的早期诊断与精准治疗[J]. 岭南现代临床外科, 2018, 18(05): 593-598.
[5]	王礼东袁晓东骆必伟谢勇田佩凯欧希林泽伟刘晓平刘吉奎陈心春张明霞. 中央记忆T细胞和效应记忆T细胞亚群在肝癌患者外周血中分布特点分析[J]. 岭南现代临床外科, 2016, 16(03): 249-253.
[6]	许侨东颜永聪黄拼搏喻志敏肖治宇. 原发性肝细胞肝癌中PinX1的表达及其临床意义[J]. 岭南现代临床外科, 2016, 16(02): 223-227.
[7]	吴海丰. 腹腔镜肝切除术在治疗肝癌的安全性及疗效分析[J]. 岭南现代临床外科, 2016, 16(01): 24-26.
[8]	胡志刚王捷. 精准医疗时代肝细胞肝癌诊疗策略[J]. 岭南现代临床外科, 2016, 16(01): 1-6.
[9]	陈捷叶义标罗兴喜张金岱鲁振环吴潇陈涛. 术后中性粒细胞／淋巴细胞比值变化对肝细胞肝癌切除术后患者预后的影响[J]. 岭南现代临床外科, 2014, 14(05): 509-512.
[10]	黄治国,黄拼搏,何传超,肖治宇. FAP-1在肝细胞肝癌中的表达及临床意义[J]. 岭南现代临床外科, 2013, 13(02): 91-94.